67% of the total technology export down payment… Strong bio venture
It was found that the volume of global technology exports of domestic pharmaceutical bio companies supported by the Ministry of Health and Welfare and the Korea Health Industry Promotion Agency reached about 7 trillion won in 2020.
The Ministry of Health and Welfare announced that the number of global technology exports succeeded last year with the support of the Ministry of Welfare and Promotion Agency reached 6,800 billion won.
This is 70% of the total amount of 10 trillion won in technology export contracts for domestic pharmaceutical bio companies in 2020 announced by the Korea Pharmaceutical Bio Association in December last year.
According to the Ministry of Health and Welfare on the 25th, last year’s global technology exports, in particular, bio-venture companies such as Alteogen, Voronoi, and Legochem Bioscience showed a strong 84% of the total.
In the case of bio-venture companies, the achievements of open innovation (open innovation) in which a global pharmaceutical company transfers the developed original technology and new drug candidates to develop it.
Alteogen’s ALT-B4 is a human recombinant hyaluronic acid degrading enzyme that can replace the formulation of intravenous antibody and protein drugs with subcutaneous drugs. ‘ALT-B4’ was developed through Alteogen’s self-developed subcutaneous injection formulation modification platform technology (Hybrozyme), and additional technology exports are expected in the future through the use of this platform technology.
Yuhan’s’YH12852′ is a treatment for gastrointestinal diseases. ‘YH12852’ is planned to be transferred to the U.S. after completing preclinical toxicity and phase 1 clinical trials in Korea, and phase 2 clinical trials will be conducted in the U.S. in 2021.
SK Biopharm’s’Senobamate’ is Korea’s first epilepsy treatment that has been independently conducted the entire process from discovery of candidate substances to global clinical development and marketing approval. ‘Senobamate’ is expected to achieve Korea’s first global blockbuster drug (sales of more than KRW 1 trillion) in the future, with technology transfer performance of up to 5788 billion won (down payment 54.5 billion won, commercialization achieved technology fee 524.3 billion won and royalties) in Japan.
Voronoi’s’VRN07′ is a candidate drug that can selectively act on non-small cell lung cancer caused by mutations in the gene (Exon 20 insertion). ‘VRN07’ is expected to be an effective treatment method for mutant non-small cell lung cancer and solid cancer patients suffering from general chemotherapy.
Legochem Bioscience’s’LCB67′ is a new drug candidate that selectively acts on various solid cancers such as cell lung cancer and liver cancer. ‘LCB67′ was developed through self-developed next-generation platform technology ADC (antibody-drug complex). Legochem Biosciences succeeded in transferring a total of 4 candidate materials to global technology including the US, China, and Europe using next-generation platform technology including’LCB67’ last year alone.
Hyeon Soo-yop, an assistant manager of high-tech medical support, said, “Because of the challenging R&D and bold investments of private companies, we were able to achieve the highest technology export performance ever.” The support project is positioning itself as an innovation partner that shares the risk of developing new drugs.”
“From 2021, we plan to further strengthen full-cycle support through national R&D projects (Ministry of Health and Welfare, Ministry of Science and Technology Information and Communication, Ministry of Trade, Industry and Energy) by removing the partition between ministries from basic research to commercialization of new drug development.”
Copyright © Shin-A Ilbo Unauthorized reproduction and redistribution prohibited